AbbVie

AbbVie is a global biopharmaceutical company headquartered in North Chicago, Illinois. It became an independent publicly traded company in 2013 after being separated from Abbott, taking with it Abbott’s established pharmaceutical research and commercial operations. AbbVie focuses on immunology, oncology, neuroscience, ophthalmology, gastroenterology, women’s health, and related therapeutic areas. Its portfolio has included Humira, Skyrizi, Rinvoq, Imbruvica, and other prescription medicines, as well as therapeutic and aesthetic products associated with the Allergan business. Humira was for many years a central product, while the company has sought to diversify its revenue base as biosimilar competition increased after the loss of key exclusivity protections. AbbVie has also expanded through research partnerships, licensing, and acquisitions, including the acquisition of Allergan. Its core business is the research, development, and commercialization of prescription medicines and related healthcare products; it is not a banking or general financial-services brand.

AbbVie was separated from Abbott in 2013 and began operating as an independent publicly traded biopharmaceutical company. At its formation, the company inherited a portfolio of established medicines and research assets, including Humira, which became a major commercial foundation in immunology. Over time, AbbVie expanded its activities across immunology, oncology, neuroscience, ophthalmology, gastroenterology, and related fields through internal research, collaborations, licensing, and acquisitions. As biosimilar competition increased following the weakening of key exclusivity protections for Humira, the company placed greater emphasis on newer immunology medicines such as Skyrizi and Rinvoq and continued to broaden its therapeutic portfolio. The acquisition of Allergan also expanded AbbVie’s presence in aesthetics, neuroscience, and ophthalmology. Its development has generally combined cash generation from established products with investment in research, new product launches, and portfolio-building transactions. Specific financial figures, transaction values, and market-level sales data are omitted here because no verifiable source URLs were provided.

1. 2020Completed Allergan transaction

   AbbVie completed the acquisition of Allergan, incorporating its aesthetics, ophthalmology, and neuroscience products and operations into the company's portfolio.
2. 2019Announced acquisition of Allergan

   AbbVie announced the acquisition of Allergan to expand its business in aesthetics, neuroscience, ophthalmology, and other specialty therapeutic areas.
3. 2013Spin-off from Abbott to form an independent company

   AbbVie was spun off from Abbott, taking over part of its pharmaceutical R&D and commercialization business, and became an independent publicly traded company.

A global research-based biopharmaceutical company focused on immunology, oncology, neuroscience, ophthalmology, gastroenterology, and aesthetics.

• HumiraImmunology biologic

  An adalimumab-based biologic used for a range of inflammatory and autoimmune diseases. It was one of AbbVie’s defining products during the company’s early development and established a major commercial foundation in immunology.

• SkyriziImmunology prescription drug

  An immunology medicine targeting a specific inflammatory pathway and used in selected chronic inflammatory diseases. It is one of AbbVie’s key newer immunology products developed to strengthen the portfolio beyond Humira.

• RinvoqImmunology small molecule drug

  An oral immunomodulatory medicine used in selected inflammatory and autoimmune conditions. It represents AbbVie’s effort to build an oral immunology franchise alongside its biologic therapies.

• BotoxAesthetic and therapeutic botulinum toxin product

  A botulinum toxin brand used in selected therapeutic indications and aesthetic procedures. It became an important part of AbbVie’s aesthetics and specialty-care portfolio through the integration of Allergan.

• ImbruvicaHematology-oncology drug

  A targeted oncology medicine used in certain hematologic malignancies. It helped AbbVie expand beyond immunology into oncology, with specific indications and availability subject to local regulatory approvals.

• VraylarNeuropsychiatric prescription drug

  A prescription medicine used in selected psychiatric and mood-disorder indications. It is one of the representative brands in AbbVie’s neuroscience portfolio, with availability and indications subject to local approvals.